Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CORAL: ART Intensification with Raltegravir and/or Bovine Colostrum
NCT00772590Phase 4Completed
- Sponsor
- The Kirby Institute
- Start
- Mar 2009
- Primary completion
- Mar 2010
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, double-blind trial of raltegravir and IMM-124E in human immunodeficiency virus type 1 infection (HIV-1) (4 arms), sponsored by The Kirby Institute. Primary endpoint: Mean Change From Baseline CD4+ T Cell Count at 24 weeks. Started Mar 2009; status: completed.
02
Drugs
raltegravirIMM-124E
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT00772590.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00772590.